Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements.
Net profit19.89 millionEGP · −51.1% vs the same period a year earlier
Total assets789 millionEGP · +23.5% vs the same period a year earlier
Shareholders' equity396 millionEGP · +10.0% vs the same period a year earlier
Operating cash flow75.15 millionEGP · +660.5% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q2 2023 was about 19.89 million EGP, down −51.1% from 40.68 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 789 million EGP, and shareholders' equity about 396 million EGP.
- Operating cash flow for Q2 2023 was positive at 75.15 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit19.89 million40.68 million−51.1%
Gross profit130 million133 million−2.8%
Total assets789 million639 million+23.5%
Total liabilities393 million279 million+41.1%
Shareholders' equity396 million360 million+10.0%
Total liabilities and equity789 million639 million+23.5%
Operating cash flow75.15 million-13.41 million+660.5%
Investing cash flow-2.42 million-1.7 million−42.0%
Financing cash flow15.6 million-24.3 million+164.2%
Net change in cash88.33 million-39.4 million+324.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy